Clinical Research Directory
Browse clinical research sites, groups, and studies.
Repurposing Low-Dose Clonidine for PTSD in Veterans
Sponsor: Wake Forest University Health Sciences
Summary
Hypothesis: Veterans with PTSD prescribed clonidine will demonstrate improvements in PTSD symptoms, including daytime, nighttime, and sleep-related behaviors.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2023-06-01
Completion Date
2027-03-31
Last Updated
2026-03-31
Healthy Volunteers
No
Conditions
Interventions
Clonidine Pill
The study will use a flexible-dose adjustment schedule to identify the minimum dose needed to alleviate symptoms while also ensuring acceptable adverse effects. In other words, all subjects will start at the minimum dose (0.1 mg/night). Near the end of every week, each subject will be assessed for symptom alleviation and adverse events by asking the patient two questions from the CAPS-5 (questions B2 and E6. At baseline, each patient will have scored a ≥3 on each of these questions. If one or both scores remain at ≥3 and if any reported adverse events are marked acceptable by both the clinician and subject, then the dosage for the following week will be increased one level according to the titration chart. However, if both scores for these questions are ≤2 and any current adverse events are acceptable, then the dosage will remain the same. Finally, if any adverse events are deemed unacceptable, the clonidine dosage will be reduced to the lowest acceptable daily dosage.
Placebo
Blinded placebo capsules will be provided to participants.
Locations (1)
Aurora Psychiatric Hospital
Wauwatosa, Wisconsin, United States